An expensive cholesterol drug, evolocumab, which is prescribed on the NHS, is claimed to do nothing to prevent fatal heart attacks and strokes and a coalition of doctors have called for it to be withdrawn from use.
Positive results from the SLS in asthma have been announced by GSK and Innoviva, demonstrating that patients initiated on treatment with Relvar Ellipta significantly improved asthma control compared with usual care.
Kancera has applied for approval of a Phase I trial for its drug candidate, KAND567, which blocks the fractalkine system. The study will be performed in collaboration with the clinical contract company QPS in the Netherlands.
A recent report from MarketIntelReports — ‘World Intravenous (IV) Ibuprofen Market — Opportunities and Forecast 2022’ — has estimated that the IV ibuprofen market will register a compound annual growth rate of 20% until 2022.
It has been announced that Chemische Fabrik Budenheim site in Budenheim, Germany, has recently been awarded an EXCiPACT GMP/GDP certificate from SGS — one of EXCiPACT’s internationally recognised certification bodies.
Dr Thomas Hein, senior vice president, commercial and regulatory affairs at Hermes Pharma examines the benefits of multiple oral solid dosage forms and their impact on certain APIs.
Biopharmaceutical company, AstraZeneca has unveiled its NiCola-B drug discovery robot, capable of performing industrial scale experiments in the search for new, life-saving medicines.
